Journal of Alzheimer s Disease Reports,
Год журнала:
2024,
Номер
8(1), С. 1211 - 1228
Опубликована: Июль 13, 2024
Background:
Alzheimer’s
disease
(AD),
one
of
the
most
prevalent
causes
dementia,
is
mainly
sporadic
in
occurrence
but
driven
by
aging
and
other
cofactors.
Studies
suggest
that
excessive
alcohol
consumption
may
increase
AD
risk.
Objective:
Our
study
examined
degree
to
which
short-term
moderate
ethanol
exposure
leads
molecular
pathological
changes
AD-type
neurodegeneration.
Methods:
Long
Evans
male
female
rats
were
fed
for
2
weeks
with
isocaloric
liquid
diets
containing
24%
or
0%
caloric
(
n
=
8/group).
The
frontal
lobes
used
measure
immunoreactivity
biomarkers,
insulin-related
endocrine
metabolic
molecules,
proinflammatory
cytokines/chemokines
duplex
multiplex
enzyme-linked
immunosorbent
assays
(ELISAs).
Results:
Ethanol
significantly
increased
lobe
levels
phospho-tau,
reduced
Aβ,
ghrelin,
glucagon,
leptin,
PAI,
IL-2,
IFN-
γ.
Conclusions:
Short-term
effects
chronic
feeding
produced
neuroendocrine
pathologic
reflective
dysregulation,
together
abnormalities
likely
contribute
impairments
neuroplasticity.
findings
rapidly
establishes
a
platform
energy
metabolism
occur
both
early
stages
alcohol-related
brain
degeneration.
Pharmaceutics,
Год журнала:
2023,
Номер
16(1), С. 58 - 58
Опубликована: Дек. 29, 2023
Alzheimer's
disease,
a
progressive
neurodegenerative
condition,
is
characterized
by
gradual
decline
in
cognitive
functions.
Current
treatment
approaches
primarily
involve
the
administration
of
medications
through
oral,
parenteral,
and
transdermal
routes,
aiming
to
improve
function
alleviate
symptoms.
However,
these
treatments
face
limitations,
such
as
low
bioavailability
inadequate
permeation.
Alternative
invasive
methods,
while
explored,
often
entail
discomfort
require
specialized
assistance.
Therefore,
development
non-invasive
efficient
delivery
system
crucial.
Intranasal
has
emerged
potential
solution,
although
it
constrained
unique
conditions
nasal
cavity.
An
innovative
approach
involves
use
nano-carriers
based
on
nanotechnology
for
intranasal
delivery.
This
strategy
overcome
current
limitations
providing
enhanced
bioavailability,
improved
permeation,
effective
traversal
blood-brain
barrier,
extended
retention
within
body,
precise
targeting
brain.
The
comprehensive
review
focuses
advancements
designing
various
types
nano-carriers,
including
polymeric
nanoparticles,
metal
lipid
liposomes,
nanoemulsions,
Quantum
dots,
dendrimers.
These
are
specifically
tailored
therapeutic
agents
aimed
at
combatting
disease.
In
summary,
utilization
systems
show
significant
surmounting
constraints
disease
strategies.
Nevertheless,
essential
acknowledge
regulatory
well
toxicity
concerns
associated
with
this
route;
meticulous
consideration
required
when
engineering
carrier.
underscores
revolutionize
management
highlights
importance
addressing
considerations
safe
implementations.
Embracing
could
lead
substantial
field
treatment.
Molecules,
Год журнала:
2024,
Номер
29(21), С. 5131 - 5131
Опубликована: Окт. 30, 2024
The
most
prevalent
chronic
neurodegenerative
illness
in
the
world
is
Alzheimer's
disease
(AD).
It
results
mental
symptoms
including
behavioral
abnormalities
and
cognitive
impairment,
which
have
a
substantial
financial
psychological
impact
on
relatives
of
patients.
review
discusses
various
pathophysiological
mechanisms
contributing
to
AD,
amyloid
beta,
tau
protein,
inflammation,
other
factors,
while
emphasizing
need
for
effective
disease-modifying
therapeutics
that
alter
progression
rather
than
merely
alleviating
symptoms.
This
mainly
covers
medications
are
now
being
studied
clinical
trials
or
recently
approved
by
FDA
fall
under
treatment
(DMT)
category,
alters
targeting
underlying
biological
DMTs
focus
improving
patient
outcomes
slowing
decline,
enhancing
neuroprotection,
supporting
neurogenesis.
Additionally,
amyloid-targeting
therapies,
tau-targeting
neuroprotective
others.
evaluation
specifically
looked
at
studies
FDA-approved
novel
Phase
II
III
development
were
carried
out
between
2021
2024.
A
thorough
US
government
database
identified
biologics
small
molecule
drugs
14
agents
I,
34
II,
11
might
be
completed
2028.
Journal of Integrative Neuroscience,
Год журнала:
2025,
Номер
24(1)
Опубликована: Янв. 20, 2025
Alzheimer’s
disease
(AD)
is
a
common
central
neurodegenerative
disorder
characterized
primarily
by
cognitive
impairment
and
non-cognitive
neuropsychiatric
symptoms
that
significantly
impact
patients’
daily
lives
behavioral
functioning.
The
pathogenesis
of
AD
remains
unclear
current
Western
medicines
treatment
are
purely
symptomatic,
with
singular
pathway,
limited
efficacy,
substantial
toxicity
side
effects.
In
recent
years,
as
research
into
has
deepened,
there
been
gradual
increase
in
the
exploration
application
medicinal
plants
for
AD.
Numerous
studies
have
shown
their
active
ingredients
can
potentially
mitigate
regulating
various
molecular
mechanisms,
including
production
aggregation
pathological
proteins,
oxidative
stress,
neuroinflammation,
apoptosis,
mitochondrial
dysfunction,
neurogenesis,
neurotransmission,
brain-gut
microbiota
axis.
this
review,
we
analyzed
comprehensively
summarized
advancements
on
AD,
along
underlying
mechanisms
clinical
evidence.
Ultimately,
aimed
to
provide
reference
further
investigation
specific
through
which
prevent
treat
well
identification
efficacious
derived
from
plants.
Molecules,
Год журнала:
2025,
Номер
30(4), С. 922 - 922
Опубликована: Фев. 17, 2025
This
study
examines
the
intricacies
of
Alzheimer's
disease
(AD),
its
origins,
and
potential
advantages
various
herbal
extracts
natural
compounds
for
enhancing
memory
cognitive
performance.
Future
studies
into
AD
treatments
are
encouraged
by
review's
demonstration
effectiveness
phytoconstituents
that
were
extracted
from
a
number
plants.
In
addition
to
having
many
beneficial
effects,
such
as
improved
cholinergic
function,
medicines
also
much
less
harmful,
more
readily
available,
easier
use
than
other
treatments.
They
pass
without
difficulty
through
blood-brain
barrier
(BBB).
focused
on
substances
their
effects
using
academic
databases
identify
peer-reviewed
published
between
2015
2024.
According
literature
review,
66
isolated
21
distinct
plants
have
shown
efficacy,
which
could
be
encouraging
future
research
therapies.
Since
most
clinical
trials
produce
contradictory
results,
suggests
larger-scale
with
longer
treatment
durations
necessary
validate
or
refute
therapeutic
efficacy
Current Topics in Medicinal Chemistry,
Год журнала:
2023,
Номер
23(13), С. 1221 - 1259
Опубликована: Апрель 11, 2023
Heterocycles
and
their
derivatives
hold
an
important
place
in
medicinal
chemistry
due
to
vast
therapeutic
pharmacological
significance
wider
implications
drug
design
development.
Piperidine
is
a
nitrogen-containing
heterocyclic
moiety
that
exhibits
array
of
properties.
This
review
discusses
the
potential
piperidine
against
neurodegenerative
disease
Alzheimer's.
The
incidences
Alzheimer's
are
increasing
nowadays,
constant
efforts
being
made
develop
agent
for
this
disease.
We
have
highlighted
advancement
developing
piperidine-based
anti-neuronal
compounds
profound
activities
some
major
piperidine-bearing
molecules
with
target
site.
focuses
on
advancements
field
natural
synthetic
occurring
piperidines
active
disease,
emphasis
past
6
years.
discussion
also
includes
structure-activity
relationship,
structures
most
promising
molecules,
biological
revealed
by
these
piperidinebased
scaffolds
undoubtedly
them
at
forefront
discovering
prospective
candidates.
Thus,
it
would
be
great
interest
researchers
working
synthesizing
neuroprotective
Molecules,
Год журнала:
2023,
Номер
28(12), С. 4802 - 4802
Опубликована: Июнь 16, 2023
Graptophyllum
pictum
is
a
tropical
plant
noticeable
for
its
variegated
leaves
and
exploited
various
medicinal
purposes.
In
this
study,
seven
compounds,
including
three
furanolabdane
diterpenoids,
i.e.,
Hypopurin
E,
A
B,
as
well
with
Lupeol,
β-sitosterol
3-O-β-d-glucopyranoside,
stigmasterol
3-O-β-d-glucopyranoside
mixture
of
stigmasterol,
were
isolated
from
G.
pictum,
their
structures
deduced
ESI-TOF-MS,
HR-ESI-TOF-MS,
1D
2D
NMR
experiments.
The
compounds
evaluated
anticholinesterase
activities
against
acetylcholinesterase
(AChE)
butyrylcholinesterase
(BchE),
antidiabetic
potential
through
inhibition
α-glucosidase
α-amylase.
For
AChE
inhibition,
no
sample
had
IC50
within
tested
concentrations,
though
the
most
potent
was
A,
which
percentage
40.18
±
0.75%,
compared
to
85.91
0.58%
galantamine,
at
100
µg/mL.
BChE
more
susceptible
extract
(IC50
=
58.21
0.65
µg/mL),
stem
67.05
0.82
58.00
0.90
B
0.92
µg/mL)
E
86.90
0.76
µg/mL).
assay,
lupeol
extracts
moderate
good
activities.
Against
α-glucosidase,
lupeol,
appreciable
but
48.90
0.17
45.61
0.56
active
than
pure
compounds.
α-amylase
64.47
0.78
60.68
0.55
69.51
1.30
standard
acarbose
32.25
0.36
Molecular
docking
performed
determine
binding
modes
free
energies
in
relation
enzymes
decipher
structure-activity
relationship.
results
indicated
that
could,
general,
be
used
development
therapies
Alzheimer's
disease
diabetes.
Journal of Drug Delivery Science and Technology,
Год журнала:
2023,
Номер
89, С. 105047 - 105047
Опубликована: Окт. 5, 2023
As
the
globe's
population
increases,
incidences
of
Alzheimer's
disease
(AD)
are
steadily
increasing.
AD
represents
most
common
neurological
disorder
and
constitutes
60–70%
all
dementia
cases.
The
accumulation
amyloid
plaques,
intraneuronal
fibrillary
tangles,
decrease
in
choline
acetyltransferase,
loss
cholinergic
neurons
considered
hallmarks
AD.
current
FDA-approved
anti-AD
drugs
can
only
inhibit
symptoms
for
a
limited
time
without
stopping
or
reversing
progression
disease.
In
addition,
their
clinical
applications
hindered
by
partial
ability
to
cross
blood-brain
barrier
(BBB),
poor
bioavailability,
systemic
adverse
effects.
Nevertheless,
nanoformulation
synthetic
natural
into
advanced
nanodelivery
systems
has
been
utilized
efficient
brain
delivery.
addition
brief
introduction
AD,
its
pathology,
treatment
options,
this
review
sheds
light
on
novel
used
recently
delivery
various
therapeutic
agents.
